Active Ingredient History
Acyclovir is a synthetic antiviral nucleoside analogue. A screening program for antiviral drugs begun at Burroughs Wellcome in the 1960s resulted in the discovery of acyclovir in 1974. Preclinical investigation brought the drug to clinical trials in 1977 and the first form of the drug (topical) was available to physicians in 1982. Activity of acyclovir is greatest against herpes 1 and herpes 2, less against varicella zoster, still less against Epstein-Barr, and very little against cytomegalovirus. Acyclovir is an antiviral agent only after it is phosphorylated in infected cells by a viral-induced thymidine kinase. Acyclovir monophosphate is phosphorylated to diphosphate and triphosphate forms by cellular enzymes in the infected host cell where the drug is concentrated. Acyclovir triphosphate inactivates viral deoxyribonucleic acid polymerase. NCATS
Drug Pricing (per unit)
Note: This drug pricing data is preliminary, incomplete, and may contain errors.
Combination drugs
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
Acne Vulgaris (Phase 3)
Anesthesia and Analgesia (Phase 4)
Bell Palsy (Early Phase 1)
Bone Marrow Transplantation (Phase 3)
Carcinoma, Non-Small-Cell Lung (Phase 2)
Chickenpox (Phase 3)
Community-Acquired Infections (Phase 3)
Critical Illness (Phase 2)
Cytomegalovirus (Phase 3)
Cytomegalovirus Infections (Phase 3)
Dermatitis, Atopic (Phase 2)
Healthcare-Associated Pneumonia (Phase 3)
Healthy Volunteers (Phase 4)
Hematopoietic Stem Cell Transplantation (Phase 2)
Herpes Genitalis (Phase 4)
Herpes Labialis (Phase 4)
Herpes Simplex (Phase 4)
Herpesvirus 2, Human (Phase 2)
Herpes Zoster (Phase 4)
HIV (Phase 4)
HIV Infections (Phase 4)
HIV Seronegativity (Phase 3)
Infections (Phase 1)
Keratitis, Herpetic (Phase 3)
Kidney Diseases (Phase 1/Phase 2)
Kidney Transplantation (Phase 1/Phase 2)
Leukemia (Phase 1/Phase 2)
Leukemia-Lymphoma, Adult T-Cell (Phase 1/Phase 2)
Leukemia, Myelogenous, Chronic, BCR-ABL Positive (Phase 1/Phase 2)
Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative (Phase 1/Phase 2)
Meniere Disease (Phase 2/Phase 3)
Multiple Sclerosis (Phase 3)
Multiple Sclerosis, Relapsing-Remitting (Phase 4)
Neonatal Sepsis (Phase 1)
Neoplasms (Phase 3)
Obesity (Phase 1)
Pain (Phase 4)
Pharmacology (Phase 3)
Pneumonia, Ventilator-Associated (Phase 3)
Pneumonia, Viral (Phase 4)
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma (Phase 1/Phase 2)
Precursor Cell Lymphoblastic Leukemia-Lymphoma (Phase 1/Phase 2)
Sexually Transmitted Diseases (Phase 3)
Simplexvirus (Phase 1)
Ulcer (Phase 2/Phase 3)
Varicella Zoster Virus Infection (Phase 4)
Warts (Phase 4)
| Trial | Phase | Start Date | Organizations | Indications |
|---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue
